文献速递物质与行为成瘾儿童青少年精神

注意缺陷多动障碍药物治疗与物质相关问题的关联

ADHD Medication and Substance-Related Problems.
PubMed 文献 · Am J Psychiatry · 2017-06-29

该研究分析2005—2014年商业健康保险理赔数据中2,993,887例青少年和成人注意缺陷多动障碍(ADHD)患者,采用个体内比较,发现接受ADHD药物治疗期间及停药2年后物质相关事件风险均较低,男性长期关联更一致。

要点

  • ADHD药物治疗期间物质相关事件风险较低,男性OR=0.65,女性OR=0.69。
  • 停药2年后物质相关事件风险仍较低,男性OR=0.81,女性OR=0.86。
  • 女性长期关联的敏感性分析结果一致性较弱。

核心结论

  • ADHD药物治疗与青少年或成人物质相关问题风险升高无关,而与同期及长期物质相关事件风险降低相关。

研究设计与样本

  • 基于2005—2014年商业健康保险理赔数据的队列研究,纳入2,993,887例青少年和成人ADHD患者,其中女性占47.2%。
  • 采用个体内分析,比较患者接受处方兴奋剂或托莫西汀治疗的月份与未接受治疗的月份中物质相关事件风险。

主要发现

  • 调整后个体内比较显示,男性接受ADHD药物治疗期间物质相关事件风险降低35%(OR=0.65,95%CI=0.64-0.67)。
  • 女性接受ADHD药物治疗期间物质相关事件风险降低31%(OR=0.69,95%CI=0.67-0.71)。
  • 男性停药2年后物质相关事件风险降低19%(OR=0.81,95%CI=0.78-0.85)。
  • 女性停药2年后物质相关事件风险降低14%(OR=0.86,95%CI=0.82-0.91)。
  • 敏感性分析支持多数发现,但女性长期关联的一致性较弱。

关键数值与推荐

  • 物质相关事件定义为与物质使用障碍相关的急诊就诊。

临床怎么用

  • 临床可参考该结果,ADHD药物治疗未显示增加物质相关问题风险,且与同期及长期风险降低相关。

局限性

  • 女性长期关联的敏感性分析结果一致性较弱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Substance use disorders are major contributors to excess mortality among individuals with attention deficit hyperactivity disorder (ADHD), yet associations between pharmacological ADHD treatment and substance-related problems remain unclear. This study investigated concurrent and long-term associations between ADHD medication treatment and substance-related events. METHOD: The authors analyzed 2005-2014 commercial health care claims from 2,993,887 (47.2% female) adolescent and adult ADHD patients. Within-individual analyses compared the risk of substance-related events (i.e., emergency department visits related to substance use disorders) during months in which patients received prescribed stimulant medication or atomoxetine relative to the risk during months in which they did not. RESULTS: In adjusted within-individual comparisons, relative to periods in which patients did not receive ADHD medication, male patients had 35% lower odds of concurrent substance-related events when receiving medication (odds ratio=0.65, 95% CI=0.64-0.67), and female patients had 31% lower odds of concurrent substance-related events (odds ratio=0.69, 95% CI=0.67-0.71). Moreover, male patients had 19% lower odds of substance-related events 2 years after medication periods (odds ratio=0.81, 95% CI=0.78-0.85), and female patients had 14% lower odds of substance-related events 2 years after medication periods (odds ratio=0.86, 95% CI= 0.82-0.91). Sensitivity analyses supported most findings but were less consistent for long-term associations among women. CONCLUSIONS: These results provide evidence that receiving ADHD medication is unlikely to be associated with greater risk of substance-related problems in adolescence or adulthood. Rather, medication was associated with lower concurrent risk of substance-related events and, at least among men, lower long-term risk of future substance-related events.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Quinn PD, Chang Z, Hur K, et al. ADHD Medication and Substance-Related Problems. Am J Psychiatry. 2017. PMID: 28659039. doi:10.1176/appi.ajp.2017.16060686

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。